

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

---

**IN RE: GENERIC DIGOXIN AND  
DOXYCYCLINE ANTITRUST LITIGATION**

---

**MDL NO. 2724  
2:16-md-02724-CMR**

**THIS DOCUMENT RELATES TO:**

***ALL ACTIONS***

---

**HON. CYNTHIA M. RUFE**

**DEFENDANT MAYNE PHARMA INC.'S  
RULE 7.1 CORPORATE DISCLOSURE STATEMENT**

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, Defendant Mayne Pharma Inc. ("Mayne"), by and through counsel, hereby states that Mayne is a direct, wholly-owned subsidiary of Mayne Pharma Group, Ltd., an Australian corporation. Mayne is not a publicly-traded entity, and Mayne Pharma Group, Ltd. is the only publicly-traded entity that owns 10% or more of the stock of Mayne.

Dated: February 22, 2017

Respectfully Submitted,

/s/ Michael Martinez

Michael Martinez

**K&L Gates LLP**

70 W. Madison St., Suite 3100

Chicago, Illinois 60602

T: 312.807.4404

F: 312.827.8116

michael.martinez@klgates.com

*Counsel for Defendant Mayne Pharma Inc.*

**CERTIFICATE OF SERVICE**

I, Michael Martinez, hereby certify that the foregoing **CORPORATE DISCLOSURE STATEMENT** was served on all counsel of record via ECF on February 22, 2017. Pursuant to Local Rule 5.1.2(8)(b), I further certify that the foregoing document is available for viewing and downloading on ECF.

Dated: February 22, 2017

/s/ Michael Martinez  
Michael Martinez